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Abstract We have used HPLC techniques to investigate the 
effects of gpl20 upon inositol phosphate turnover in Jurkat E6-1 
CD4+ T-cells, to pursue previous reports that this viral coat 
protein: (a) inhibits receptor-activated inositol phosphate re-
lease; (b) stimulates basal inositol phosphate release; (c) inhibits 
inositol polyphosphate 5-phosphatase. Treatment of cells with up 
to 10 ug/ml gpl20 from between 10 min and 24 h was without 
effect upon inositol phosphate turnover in both basal cells, and in 
C305 and OKT3 stimulated cells. This is the first report that 
biologically competent gpl20 does not affect any aspect of 
inositol phosphate turnover in either basal or receptor-activated 
lymphocytes. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Circulating, free gpl20 is believed to contribute to the non-
infective actions of the HIV virus [1-3]. In particular, there is 
considerable interest in the possibility that gpl20 can perturb 
the normal functions of peripheral CD4+ T-lymphocytes by 
modulation of phospholipase C (PLC) activity. The latter en-
zyme hydrolyzes phosphatidylinositol (4,5)P2 to yield two in-
tracellular signals: diacylglycerol, which activates protein ki-
nase C, plus Ins(l ,4,5)^3, which mobilizes intracellular [Ca2+] 
[4,5]. Specifically, it has been reported that gpl20 inhibits 
CD3-mediated production of inositol phosphates in the 
P28D T cell clone by up to 50% [6]. More recently, it was 
proposed that the latter effects arose from inhibition of recep-
tor-dependent tyrosine phosphorylation of PLC-y [7]. Thus, 
gpl20 may contribute to the pathogenesis of HIV infection 
by decreasing the efficiency with which the occupied receptor 
activates PLC, thereby diminishing the proliferative response 
to antigen. To our knowledge, no independent laboratory has 
described an attempt to pursue the significance of this descrip-
tion of gpl20-mediated perturbation of receptor-dependent 
inositol phosphate signalling. This was therefore our goal, 
but with the proviso that the most rigorous and sensitive 
procedures be employed, namely, HPLC separation and indi-
vidual analysis of the full range of inositol polyphosphates 
that occur inside T-cells [8]. We chose the Jurkat E6-1 
CD4+ cell line for these experiments, as they are a well-char-
acterized model for the study of PLC-dependent cell signalling 
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and have been used extensively to study the interaction of 
gpl20 and CD4 [2,9-13]. In addition, Jurkat cells are very 
permissive for HIV infection [13]. These cells also display 
appropriate receptor-mediated interactions of CD4 with the 
rest of the TCR complex [14]. 
Other workers have suggested there is an additional target 
of gpl20 in T-cells, namely, inhibition of the inositol poly-
phosphate 5-phosphatase [15]; such an effect was believed to 
contribute to the elevated levels of these inositol polyphos-
phates observed in lymphocytes prepared from HIV-infected 
individuals, which would be anticipated to result in inappro-
priate cellular activation [15-17]. These ideas have been high-
lighted as being of considerable interest [18], but to date they 
have not been independently confirmed. We therefore inves-
tigated if we could detect any effect upon 5-phosphatase fol-
lowing the treatment of T-cells with gpl20. 
A third means by which gpl20 has been reported to perturb 
inositol phosphate signalling in lymphocytes is by activation 
of receptor-independent (basal) PLC activity, leading to im-
proper Ins(l,4,5)P3 -mediated Ca
2+ signalling [19]. However, 
two other groups have been unable to reproduce these data 
[9,20]. On the other hand, the value of a description of gpl20 
failing to elicit a biological effect is critically dependent upon 
the viability of the protein being unequivocally demonstrated. 
This problem is illustrated by a report that several prepara-
tions of gpl20 made available to the research community were 
biologically inactive [21]. Indeed, it has been a cause of some 
concern for many years that the extent to which a preparation 
of gpl20 is glycosylated, and the methodology used to purify 
it, may both impact upon its activity [22,23]. When Kaufmann 
et al. (1992) reported that gpl20 did not affect signalling in 
T-cells, they indicated that their gpl20 still bound to CD4, 
but others have shown that this property can be retained by 
biologically inactive gpl20 [21]. Our goal was to avoid these 
problems of interpretation, so when we investigated the effects 
of gpl20 upon inositol phosphate signalling, we used a prep-
aration of recombinant gpl20 that has previously been shown 
to be biologically indistinguishable from viral gpl20 
[21,24,25]. We also utilized a range of bioassays to verify 
the activity of our gpl20 preparations. 
2. Materials and methods 
2.1. Chemicals and reagents 
[3H]myo-inositol was purchased from American Radiolabelled 
Company (St. Louis, MO). [3H]thymidine was purchased from New 
England Nuclear (Boston, MA). FCS and gentamicin were purchased 
from Gibco BRL Life Technologies (Grand Island, NY). Methionine 
sulfoximine was obtained from Sigma Chemical Company (St. Louis, 
MO). OKT3 antibody (an anti-CD3 antibody) was obtained from the 
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Division of Cancer Treatment, National Cancer Institute, MD. C305 
ascites was a kind gift from Dr. A. Weiss (University of California at 
San Francisco). C305 is an anti-TCR antibody which is largely de-
pendent upon CD4 compared to OKT3 which is mostly independent 
of CD4. Human phycoerythrin-conjugated anti-CD3 and anti-CD4 
antibodies were purchased from Becton Dickinson (San Jose, CA). 
Quantum Simply Cellular Microbeads Kit was purchased from Sigma 
Chemical Co. Adsorbosphere HPLC columns were purchased from 
Alltech Associates (Deerfield, IL). Ion-exchange resin (Ag 1-X8 
200-400 mesh, formate form) was purchased from Bio-Rad (Melville, 
NY). Media (RPMI-1640, DMEM-S, GMEM-S) was kindly provided 
by the media preparation team at the National Institute of Environ-
mental Health Sciences. 
2.2. Cell culture 
Jurkat E6-1 cells, obtained from Advanced Biotechnologies (Co-
lumbia, MD), were cultured in RPMI-1640 medium supplemented 
with 10% FCS and 50 ug/ml gentamicin. ADP240/17.1 Chinese ham-
ster ovary cells, expressing the full length recombinant HIVmB (gpl20, 
see ref 25 for details), were obtained from Celltech Therapeutics Lim-
ited through the Medical Research Council AIDS Directed Pro-
gramme Reagent Project (UK). ADP240/17.1 CHO cells were grown 
in 850 cm2 roller bottles in GMEM-S media supplemented with 10% 
FCS and 200 uM methionine sulfoximine. When cells reached conflu-
ency, the media was changed to DMEM-S supplemented with 0.5% 
FCS. After 7 days the media was removed, clarified by 0.22 um 
nitration and frozen at —30°C. This process was repeated until a 
sufficient volume (usually about 2 liters) was available for purification 
of gpl20. 
2.3. [sH]-thymidine incorporation 
Jurkat cells were plated at 5X105 cells/ml in a 24 well plate at a 
volume of 250 ul in triplicate. [3H]thymidine (1 uCi/ml) was added to 
the cells and a time course (0, 0.5, 1, 2, 3 h) in the presence and 
absence of a 23 h pretreatment of 1 |xg/ml gpl20 was performed. 
The reaction was terminated by addition of 1 ml 10% TCA. The cells 
were vacuum filtered and washed 3 times with 5 ml 10% TCA. The 
radioactivity in the filter was determined by liquid scintillation. 
2.4. Flow cytometry 
Flow cytometry was performed using a FACStarPLUS Fluorescence-
Activated Cell Sorter (Becton Dickinson, San Jose, CA) equipped 
with a Coherent INNOVA 90 laser tuned to an excitation wavelength 
of 488 nm and operated at 200 mW. Fluorescence was determined 
using a 575/26 bandpass filter. Ten thousand events were collected per 
data file. Jurkat cells were washed in PBS and 106 cells were incubated 
with saturating concentrations of either anti-CD3 or anti-CD4 anti-
bodies. The Quantum Simply Cellular Microbeads kit was used to 
quantitate the fluorescence. 
2.5. Inositol phosphate assay 
Jurkat cells were labelled with 50 |iCi/ml [3H]inositol for 96 h. At 
that time, medium was removed and the cells were washed twice in 
Krebs-Ringer buffer (115 mM NaCl, 5.4 mM KC1, 0.96 mM NaH2 
P0 4 , 1.35 mM CaCl2, 0.6 mM MgS04 , 11 mM glucose, 25 mM 
HEPES, pH 7.4) without added [3H]inositol. Cells were further incu-
bated in the presence or absence of OKT3, C305, and gpl20 as de-
scribed in the figures. Incubations were quenched with perchloric acid, 
neutralized with freon/octylamine and analyzed on an Adsorbosphere 
SAX HPLC column as described previously [26,27]. Radioactivity in 
the HPLC eluate was measured on-line [27]. The identification of 
inositol phosphate peaks was by co-elution with standards and by 
comparison with the published characteristics of this HPLC system 
[26,27]. Since cellular lnsP$ was unaffected by any of the experimental 
procedures employed in this study (Fig. 1 and data not shown), the 
levels of individual inositol phosphates were frequently normalized to 
the level of InsPg in order to compensate for any sampling variability 
that may have occurred. 
2.6. gpl20 purification 
The gpl20 was purified exactly as described by Moore et al., [25]: 
the frozen media containing gpl20 was thawed and then loaded onto 
an affinity-purified sheep anti-human immunodeficiency gp 120-1 col-
umn. The column was washed using TBS (25 mM Tris, 2.7 mM KCL, 
136 mM NaCl, pH 7.5). The bound glycoprotein was eluted with 2 M 
MgCl2, gpl20 was concentrated using Centriplus 30 concentraters and 
buffer exchanged with 20 mM Tris pH 7.5. Mg2+ concentration in the 
final gpl20 buffer exchange was determined by using the fluorescent 
indicator dye mag-fura-2 and was found to be less than 35 mM (data 
not shown). Protein was stored at 4°C and used in experiments within 
one month. Purity was determined by SDS-PAGE analysis, visualized 
with diamine silver staining [10]. After transfer of proteins to Immo-
bilon-P membrane, the blot was reacted with the D7324 Ab (an af-
finity purified sheep anti human immunodeficiency gpl20 Ab) to de-
tect the gpl20. No degradation products were observed and gpl20 
migrated at approximately 120 kda (data not shown). The concentra-
tion of purified gpl20 was determined by a Bradford assay and by an 
ELISA. 
2.7. 5-Phosphatase assay on Jurkat T-cells 
105 and 2X10B Jurkat cells were incubated in 100 u,l of 0.2 mg/ml 
saponin, 20 mM HEPES, 100 mM KC1, 10 mM NaCl, 5 mM MgS04, 
1 mM EDTA with or without OKT3 and/or gpl20 for 5,10, 15 min at 
37°C with 50 itM Ins(l,4,5)P3 and 10000 dpm of [
3H] Ins(l,4,5)P3. 
Reaction was stopped by addition of 30 u.1 of 2 M HCIO4 plus 1 mg/ 
ml InsP6, neutralized with 1.2 M KOH/75 mM HEPES/60 mM 
EDTA, and analyzed by gravity-fed ion-exchange chromatography 
as described [28]. 
3. Results 
3.1. Biological activity of gp!20 
For our studies the species of gp l20 that we have used is 
identical to that which several other groups have rigorously 
defined to be biologically indistinguishable from viral gp l20 
[21,24,25]. The recombinant and native proteins have similar 
affinities for CD4 [25] and similar effects on cell physiology 
[1,24]. We purified the gp l20 exactly as first described by 
Moore et al., [25]. These workers previously verified that these 
purification procedures did not lead to any significant degra-
dation of gpl20, as assayed by SDS-PAGE and Western blots 
[25]. We used the same procedures to determine that the pu-
rity of our gp l20 [[10], data not shown] was identical to that 
of Moore et al. [25]. 
In order to optimize the biological activity of our prepara-
Table 1 
Effect of acute treatment with gpl20 upon inositol phosphate levels in 
Control 
C305 
OKT3 
Ratio (+gpl20/-gpl20) 
InsPi 
0.99 ±0.04 
1.19±0.14 
1.02 ±0.02 
InsP2 
0.92 ±0.06 
0.95 ±0.03 
0.95 ± 0.06 
Ins(l,3,4)P3 
0.89 ±0.07 
1.40 ±0.48 
1.03 ±0.04 
Ins(l,4,5)P3 
0.92 ±0.07 
0.68 ±0.46 
1.11 ±0.06 
control and antibody-stimulated Jurkat cells 
Ins(l,3,4,6)P4 
1.23 ±0.12 
1.09 ±0.03 
1.06 ±0.06 
Ins(l,3,4,5)P4 
0.83 ± 0.07 
1.01 ±0.08 
1.11 ±0.07 
Ins(3,4,5,6)P4 
1.05±0.11 
1.02 ±0.05 
1.15±0.05 
Ins(l,3,4,5,6)P5 
1.05 ±0.03 
1.01 ±0.05 
1.04 ±0.02 
Cells were labelled with [3H]inositol for 96 h as described in the Methods (Section 2), except that either gpl20 (1 u,g/ml) or vehicle were present for 
the last 24 h of labelling. The culture medium was then replaced with HEPES-buffered Krebs solution, and fresh gpl20 was added to the gpl20-
treated cells. After a further 10 min, cells were treated with OKT3 or C305 of vehicle for 10 min. Then the levels of inositol phosphates were 
determined as described in the Methods (Section 2). The results represent the ratios obtained in the presence vs the absence of gpl20 (means 
± standard errors) from four independent experiments (two in the case of C305). 
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tion of gpl20, we frequently used it within one week of its 
purification, and we routinely discarded material that were 
more than one month old. Additionally, we employed several 
independent bioassays to confirm the viability of our prepa-
rations. We established that our gpl20 reproduced (with sim-
ilar potency) the stimulation, by other active gpl20 prepara-
tions, of potassium channel activity in the plasma membrane 
of primary rat astrocytes [[24]; D.J. Benos, personal commu-
nication]. Additionally, our gpl20 reproduced the results of a 
study by Dawson et al. [29], in that it had dose-dependent 
toxic effects upon mixed neocortical neuronal-glial cell cul-
tures [L.-Y. Kong, personal communication]. Consistent 
with the idea that the latter effect is specifically neurotoxic, 
up to 23 h pre-incubation with 1 |xg/ml gpl20 has no appreci-
able effect on the DNA synthesis of Jurkat cells, as measured 
by [3H]thymidine incorporation (data not shown). Finally, 
our gpl20 increased the auto-phosphorylation of the protein 
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Fig. 2. Time course of inositol polyphosphate production in re-
sponse to anti-CD3 antibodies OKT3 and C305 in Jurkat cells. Lev-
els of inositol phosphates were determined as described in the 
legend to Fig. 1, for cells treated for the indicated time with either 
10 itg/ml OKT3 (upper panel) or 1:1000 C305 ascites dilution (low-
er panel). Data shown are from a single data set for Ins(l,3,4)P3 
(■), Ins(l,4,5)P3 ( A ) , Ins(l,3,4,5)P4 (▼) and Ins(l,3,4,6)P4 (♦). 
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Fig. 1. HPLC elution of [3H]inositol phosphates from basal Jurkat 
cells incubated either in the presence or absence of gpl20. 
[3H]inositol-labelled Jurkat T-cells were incubated with either 0.5 ug/ 
ml gpl20 or vehicle for 30 min, and then the intracellular inositol 
phosphates were analyzed by HPLC as described in the Methods 
(Section 2). The integrated c.p.m. for each peak is as follows (these 
are given in pairs, first for control cells (upper panel) followed by 
the data for gpl20-treated cells (lower panel): peak A, inositol = 
578406/580805; peak B, glycerophosphoinositol = 13721/13604; 
peak C, Insi1! = 18 166/18565; peak D, InsP2 = 9083/9546; peak E, 
Ins(l,3,4)P3 = 359/341; peak F, Ins(l,4,5)P3 = 91/90; peak G, 
Ins(l,3,4,6)P4 = 365/370; peak H, Ins(l,3,4,5)P4 = 39/42; peak I, 
Ins(3,4,5,6)P4 = 717/752; peak J, Ins(l,3,4,5,6)P5 =4882/4865; peak 
K, InsP„ = 10796/10768. 
tyrosine kinase p56lck in a human monocyte cell line [10], in 
confirmation of several other reports [7,11,30]. We therefore 
conclude that our gpl20 preparations have inherent biological 
activity, even though no single specific interaction appears to 
explain these various phenomena. 
Many of the biological effects of gpl20 arise from interac-
tion of the viral coat protein with CD4. We therefore chose 
the CD4+ Jurkat E6-1 cell line for our experiments. Jurkat 
cells have previously been used as model systems for studying 
both the gpl20/CD4 interaction and HIV infection [13]. In 
addition, we used flow cytometry to assay the relative 
amounts of CD3 and CD4 receptor numbers (see the Methods 
in Section 2 for details). We estimated that our Jurkat cells 
expressed 28 000 CD3 receptors/cell and about 6000 CD4 re-
ceptors/cell as assayed by antibody binding (data not shown; 
see the Methods in Section 2 for details). 
3.2. The effects of gpl20 upon basal phospholipase C activity 
The most physiologically relevant assay for PLC involves 
the measurement of turnover of Ins(l,4,5)P3 and its metabo-
lites in intact cells that have been equilibrium-labelled with 
[3H]inositol. Li+ is widely used as a metabolic inhibitor to 
'trap' newly-released inositol phosphates. Unfortunately, Li+ 
has non-specific effects on signal transduction, including at-
tenuation of Ins(l,4,5)P3 signals, and elevation of basal levels 
of inositol phosphates [8]. The use of Li+ in earlier studies 
[6,9,19] may have contributed to the inconsistent data on the 
effects of gpl20 upon basal inositol phosphate metabolism 
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Fig. 3. HPLC elution of [3H]inositol phosphates from Jurkat cells 
stimulated with either OKT3 or C305. Jurkat cells were labelled 
with [3H]inositol as described in the legend to Fig. 1 and then 
stimulated with either OKT3 (10 ug/ml for 2 min) or C305 ascites 
(1:1000 dilution for 2 min). Inositol phosphates were analyzed by 
hplc as described in the Methods (Section 2). The integrated c.p.m. 
for each peak is as follows (these are given in pairs, first for OKT3 
(upper panel) followed by the data for C305 (lower panel): peak A, 
inositol = 429 057/429 277; peak B, glycerophosphoinositol = 7530/ 
7551; peak C, ImPx = 17808/19960; peak D, InsP2 = 16087/15 841; 
peak E, Ins(l,3,4)P3 =939/961; peak F, Ins(l,4,5)P3 = 1953/2165; 
peak G, Ins(l,3,4,6)P4 = 107/130; peak H, Ins(l,3,4,5)P4 = 1557/ 
1477; peak I, Ins(l/3,4,5,6)P4 = 301/306; peak J, Ins(l,3,4,5,6)P5 = 
3152/3311; peak M, InsP6 = 8298/8566. 
gpl20 would impede normal receptor-dependent activation of 
phospholipase C in T-cells, since this has previously been 
reported to be a property of the viral coat protein [6]. There-
fore, we first checked that our Jurkat T-cells would exhibit the 
expected response to OKT3 antibody alone. We followed the 
protocol adopted by other workers who have studied inositol 
phosphate turnover in Jurkat T-cells [12,32,33] namely, we 
stimulated the cells with a saturating concentration of 
OKT3 antibody within 30 min of their transfer from the cul-
ture medium into serum-free medium. In such experiments we 
observed a characteristic 2-fold increase in intracellular levels 
of Ins(l,4,5)^3, followed by 24-fold and 9-fold elevations in 
levels of its downstream metabolites, Ins(l,3,4,5)P4 and 
Ins(l,3,4)P3, respectively (Figs. 2 and 3). The degree of this 
stimulation compares favorably with earlier studies [12,32,33] 
and as such is testimony to the metabolic integrity of our cells. 
However, it was notable that the incubation of Jurkat cells for 
more prolonged times in the absence of serum, before the 
addition of OKT3, led to a decline in the ensuing response 
of PLC. After incubation for 1 h in the absence of serum the 
PLC response declined to about 50% of its initial, maximal 
value. Another factor that tends to desensitize the response of 
Jurkat cells to receptor-activation is internalization of the li-
gand-bound TCR receptor [12]. We minimized the consequen-
ces of these effects by generally completing all our experiments 
within 30 min of the removal of cells from the culture me-
dium, and by always comparing incubations that contained 
gpl20 with time-matched controls. 
The OKT3 antibody recognizes epitopes on CD3-epsilon 
[34]. Other workers have shown that T-cell responses to 
anti-CD3-epsilon antibodies were virtually unaffected by 
anti-CD4 antibodies [32]. We therefore also used the anti-
TCR antibody C305 as an alternative stimulus, since this is 
largely dependent upon CD4 [32]. When a saturating concen-
tration of C305 was added to the Jurkat cells, the pattern of 
inositol phosphates produced was not significantly different 
from that initiated by OKT3, either in degree or in the 
time-course (Figs. 2 and 3). Note also that the prominent 
nature of the C305 response confirms that an appropriate 
number of functional CD3/CD4 co-receptor complexes were 
available on the cell surface. 
(see Introduction). Rather than use Li+, we improved assay 
sensitivity by high-specific activity labelling with [3H]inositol. 
The concentration of free gpl20 in HIV infected individuals 
can be as high as 1 Ug/ml [31]. We investigated the effects of a 
variety of gpl20 concentrations (0.05 ug/ml to 10 ug/ml) for 
relatively short times (10, 30, and 60 min, « = 4). In none of 
these experiments did we detect any significant effect of gpl20 
upon the levels of any inositol phosphate (Fig. 1 and data not 
shown). We also investigated the effect of incubating Jurkat 
cells with 1 ug/ml gpl20 for 24 h (« = 4), and in this case the 
coat protein was added to the culture medium during the final 
24 h of the labelling with [3H]myo-inositol. Again, there was 
no significant effect upon the inositol phosphate profile 
(Table 1). 
3.3. Receptor-mediated stimulation of PLC activity in 
Jurkat T-cells 
An important goal of our study was to investigate whether 
-g P 120 
- control 
5 10 
time (min) 
Fig. 4. Effect of gpl20 treatment of Jurkat cells upon Ins(l,4,5)P3 
5-phosphatase activity. Jurkat cells were incubated in cell culture 
media in the presence (■) and absence ( A ) of 1 |ig/ml gpl20 over-
night, then washed three times in reaction buffer and incubated with 
50 uM Ins(l,4,5)P3 and a trace amount of [
3H]Ins(l,4,5)P3. Inositol 
phosphates were separated by gravity-fed ion-exchange chromatog-
raphy as described in Section 2. 
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3.4. The effects of gpl20 upon receptor-activated 
phospholipase C activity 
One group has reported that gpl20 inhibits receptor-acti-
vated phospholipase C activity in lymphocytes [6,7]; as far as 
we are aware, this provocative result has not been pursued by 
other laboratories. We treated cells with a variety of gpl20 
concentrations (0.05 ug/ml to 10 ug/ml) for 10, 30, 60, and 120 
min, and for 24 h, and we never observed a significant effect 
of gpl20 upon either the C305-mediated or the OKT3-medi-
ated increases in levels of inositol phosphates (Table 1). Note 
that the data in Table 1 were obtained after 10 min activation 
of PLC. We also did not detect any effects of gpl20 upon the 
levels of inositol phosphates when we monitored the time-
course of PLC activation from 30 s to 20 min (data not 
shown). The concentrations of gpl20 that we used are within 
the range that Cefai et al. [6] previously proposed was suffi-
cient to inhibit both PLC and the proliferative response to 
antigen in T-cells. 
3.5. 5-Phosphatase assay on Jurkats 
A specific 5-phosphatase which metabolizes Ins(l,4,5)P3 
and Ins(l,3,4,5)^4 to physiologically inactive derivatives, is 
an important signaling 'off switch' and so its activity is tightly 
regulated [8,34]. Nye et al. [15,17] suggested that lymphocyte 
5-phosphatase might be inhibited in HIV infected individuals, 
and they further indicated that this effect was brought about 
by exposure of T-cells to free gpl20. If such an effect had 
occurred in our experiments, we would have anticipated de-
tecting higher intracellular levels of Ins( 1,4,5)^3 and 
Ins(l,3,4,5)^4 in gpl20-treated Jurkat cells; no such effect 
was observed (Fig. 1; Table 1). Nevertheless, we also checked 
the effect of gpl20 upon 5-phosphatase directly, by incubating 
Jurkat T-lymphocytes in the presence and absence of 1 ug/ml 
gpl20 (2 or 24 h preincubation in cell culture media), either 
with or without 10 ug/ml OKT3 for 10 min (« = 4). The cells 
were then rapidly permeabilized with detergent, and 5-phos-
phatase activity was immediately measured. We never ob-
served an effect of gpl20 upon 5-phosphatase activity, both 
when the concentration of Ins(l,4,5)P3 was 50 uM in order to 
saturate the enzyme (Fig. 4) and when 5 or 15 uM 
Ins(l,4,5)P3 was used (data not shown), which is below and 
at the Km value for 5-phosphatase, respectively [8]. 
4. Discussion 
Kornfeld et al. [19] reported that 2 ug/ml gpl20 stimulated 
basal PLC activity in T-cells, thereby elevating Insi^ levels 
50-fold at 10 min. In contrast, we have demonstrated that 
gpl20 has no significant effect upon inositol phosphate pro-
duction and metabolism in the human Jurkat E6-1 cell line. 
Our conclusion that gpl20 does not alter basal phospholipase 
C activity in lymphocytes (Fig. 1; Table 1) is in agreement 
with two other reports [9,20]. However, the new feature of our 
data that is of particular value is that we have used a prepa-
ration of gpl20 that was rigorously demonstrated to possess 
inherent biological activity. The reason that we have been 
unable to reproduce the data published by Kornfeld et al. 
[19] may be because it was not gpl20 that stimulated basal 
PLC activity in T-cells in their study, but a contaminant in 
their original preparation of coat protein. In this respect, it 
should be noted that the preparations used by Kornfeld et al. 
[19] were only 50% gpl20, whereas our protein was purified to 
homogeneity [10]. Our data (Figs. 1 and 3; Table 1) also fail 
to provide any support for the proposal [15,17] that exposure 
of T-cells to free gpl20 leads to an inhibition of the inositol 
polyphosphate 5-phosphatase. In view of our finding, we be-
lieve it is now of particular importance to consider alternative 
explanations to account for the observation [15,17] that 
T-cells from HIV-positive individuals may contain elevated 
levels of Ins(l,4,5)P3 and Ins(l,3,4,5)^4. This is not only rel-
evant from the point of view of understanding the molecular 
mechanisms that underlie pathological actions of HIV, but in 
addition the reported effects upon 5-phosphatase were said to 
be of diagnostic value [15,17]. 
We have also shown that the incubation of T-cells for up to 
24 h with gpl20 has no effect upon receptor-activated PLC 
activity. This is a particularly important result because it is 
apparently the first to contradict an early report that a similar 
treatment with gpl20 inhibited receptor-activated PLC activ-
ity in T-cells [6]. At present we cannot account for this differ-
ence in results. The authors of this earlier study [6] have 
recently further indicated that 16 h exposure to gpl20 also 
inhibits receptor-dependent phosphorylation of PLC [7]. 
However, to achieve the latter effect, Hubert et al. [7] used 
supra-pathological concentrations of gpl20 (30 ug/ml), con-
siderably in excess of those employed in their earlier work 
(1-4 ug/mi) [6]. Even then, the estimated degree of the effect 
upon PLC phosphorylation was only 30% [7]. While the data 
by Hubert et al. [7] are consistent with reports by several 
laboratories, including our own, that p56lck kinase activity is 
perturbed by extracellular gpl20 [10,11,30], our new data 
underscore the importance of conducting studies with patho-
logically-relevant concentrations of the coat protein. In con-
clusion, our study into the effects of biologically active gpl20 
makes a strong case that inositol phosphate signalling in 
T-cells is not generally targeted by this coat protein. We be-
lieve this is an important step forward towards the ultimate 
goal of understanding the contributions that gpl20 makes 
towards the immunopathogenesis of HIV infection. 
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